Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Inclusion Criteria

• •Histological or cytological diagnosis of locally advanced or metastatic solid tumors known to have approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents
• •Have exhausted (or refuse) all available standard of care therapy (e.g., including anti-PD1/programmed death ligand 1 \[PDL1\] if applicable) or for whom no standard therapy is available for their tumor type
• •Patients with prior anti-PD1/PDL1 must have documentation of primary or secondary resistance to last prior anti-PD1/PDL1 therapy according to Immunotherapy Resistance Committee (SITC) (Kluger et al, 2020)
• •Have at least 1 measurable lesion by RECIST 1.1 that has not been previously irradiated (for Part 2 only)
• •Have recently obtained archival tumor tissue sample available, or undergo de novo tumor biopsy
• •Eastern Cooperative Oncology Group (ECOG) PS 0-1
• •Adequate hematologic, renal, and liver functions
• •Dose Escalation (Part 1A and 1B): Any advanced or metastatic solid tumor fulfilling other relevant eligibility criteria.
• •Dose Expansion (Part 2): Tumor specific cohorts (NSCLC, RCC, melanoma, MSS CRC) must have received prior approved therapies (Part 2)